Royalty Pharma plc reported strong financial results for the fourth quarter and full year 2024 on February 11, 2025. For the full year 2024, the company deployed $2.8 billion of capital on value-enhancing royalties. Fourth quarter 2024 Royalty Receipts increased by 12% to $729 million compared to $651 million in Q4 2023, driven by strong growth from Evrysdi, the cystic fibrosis franchise, Trelegy, Xtandi, and Tremfya.
The company introduced its full year 2025 Portfolio Receipts guidance, expecting a range of $2.975 billion to $3.125 billion, representing an anticipated growth of 4% to 9%. This guidance excludes contributions from future transactions and borrowings. Total interest paid is anticipated to be approximately $260 million in 2025.
In January 2025, Royalty Pharma's Board of Directors authorized a new $3 billion share repurchase program, replacing the unused $465 million from the previous program. The company intends to repurchase $2 billion of its shares in 2025, subject to market conditions, demonstrating confidence in its business and the attractive value of its shares. For full year 2024, Royalty Pharma repurchased approximately eight million Class A ordinary shares for $230 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.